Uncategorized
NICE recommends Eylea for myopic choroidal neovascularization
The National Institute for Health and Care Excellence has given final positive recommendation for Eylea for the treatment of visual impairment due to myopic choroidal neovascularization, according to a Bayer press release.In the phase 3 MYRROR study, Eylea (aflibercept) achieved “sustained and clinical meaningful visual improvements” over 48 weeks in patients with myopic CNV.